Gilead Sciences’ antiviral COVID-19 drug remdesivir, sold under the brand name Veklury, was approved by the FDA Thursday to treat patients who have been hospitalized with the virus.
Oct.22 (UPI) — The U.S. Food and Drug Administration on Thursday approved remdesivir as a treatment for COVID-19, drugmaker Gilead Sciences announced. Gilead, which sells remdesivir under the brand name Veklury, issued a statement saying it was the first drug to be approved to treat COVID-19 patients that require hospitalization after previously being authorized by the FDA for emergency use.
